The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksASLR.L Regulatory News (ASLR)

  • There is currently no data for ASLR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Intrinsic Capital (Jersey) Ltd

1 Sep 2020 07:00

RNS Number : 5598X
Asimilar Group PLC
01 September 2020
 

The information contained in this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon publication of the announcement via a regulatory information service, this information is considered to be in the public domain.

1 September 2020

 

 

Asimilar Group plc

 

('Asimilar' or the 'Company')

 

Agreement to acquire Intrinsic Capital (Jersey) Limited

 

Equity interest and warrant in Dev Clever

 

Board appointment

 

Total Voting Rights

 

Asimilar Group plc (AIM: ASLR), the AIM quoted investing company focused on technology opportunities in the fields of big data, machine learning, telematics and the Internet of Things (IoT), is pleased to announce that it has agreed to purchase Intrinsic Capital (Jersey) Limited ("ICJL").

ICJL is a Jersey incorporated company that is wholly owned by Mark Horrocks, the founder and Chief Executive of Intrinsic Capital LLP. The acquisition will allow the Asimilar to manage its portfolio with the benefit of the more benign capital gains tax regime available in Jersey in respect of some of its current and future investments.

In addition, ICJL is a party to an investment agreement with Dev Clever Holdings Plc ("Dev Clever"), as announced by Dev Clever on 13 May 2020, giving ICJL a right to subscribe for up to 100,000,000 ordinary shares in Dev Clever at a price of 10 pence per Dev Clever share (the "Dev Clever Investment Agreement") and, following the exercise of all of these subscription rights, ICJL will be entitled to exercise a warrant to subscribe for up to 50,000,000 additional Dev Clever shares at a price of 25 pence per Dev Clever Share (the "Dev Clever Warrant"). The terms of the Dev Clever Investment Agreement have been varied from those announced by Dev Clever on 13 May 2020 and 27 July 2020 in that:

a) Dev Clever is now able to issue the balance of 17,500,000 Dev Clever shares of the original first tranche of subscription shares without the need to publish a prospectus and consequently ICJL has agreed to subscribe for the 17,500,000 Dev Clever shares for £1.75 million, on or before 4 September 2020; and 

b) Dev Clever will now use reasonable endeavours to publish a prospectus by a revised back stop date of 31 October 2020 to enable the remaining tranches of the Dev Clever Investment Agreement along with the related warrant to be issued to ICJL. The subscription rights relating to the remaining tranches are conditional on the publication of the prospectus on or before 31 October 2020.

As announced by Dev Clever on 27 July 2020, ICJL has subscribed £250,000 for Dev Clever shares pursuant to the Dev Clever Investment Agreement and, accordingly, ICJL will be acquired by the Company with an existing holding of 2,500,000 Dev Clever Shares. As at 31 July 2020 ICJL also had approximately £13,000 of cash. To date ICJL has been funded personally by Mark Horrocks who has subscribed for £25,000 of equity and has provided loans in the region of £320,000 to ICJL. It is the intention of the Company to repay these loans following completion of the acquisition of ICJL by Asimilar. As at 31 July 2020 ICJL has net liabilities of approximately £56,000 and has had minimal revenues to date.

The agreement provides that the Company will acquire the entire issued share capital of ICJL in return for the issue of 1,000,000 new Asimilar ordinary shares credited as fully paid ("Consideration Shares"). The agreement is conditional on the admission of the Consideration Shares to trading on AIM.

In addition Mark Horrocks, the sole owner of ICJL, has been granted warrants to subscribe for up to 9,000,000 Asimilar ordinary shares in 2 tranches of up to 4,500,000 warrants per tranche. Each tranche will be exercisable for two years after the relevant price criteria having been reached. The relevant price criteria are the mid-market closing price of Dev Clever Shares for a period of five consecutive Business Days being or exceeding (i) 28 pence; and (ii) 55 pence respectively.

The number of warrants which Mr Horrocks will be able to exercise will be proportional to the number of shares in Dev Clever subscribed by the Company or ICJL pursuant to the Dev Clever Investment Agreement at the date of exercise of such warrants.

Following completion of the acquisition and, subject to due diligence, Mark Horrocks has provisionally agreed join the board of Asimilar, subject to standard regulatory approvals.

Mark Horrocks has over 37 years' experience in financial markets and has been involved mainly in large scale institutional fund management. He has worked as a research analyst & fund manager for a FTSE100 insurance group. In addition, he has always maintained a keen interest in supporting smaller companies and identifying nascent opportunities as investor and supporting as mentor and, on occasion, board member. In 1997 Mark co-founded Intrinsic Capital Partnership Limited, in order to self-manage the Intrinsic Value PLC Investment Trust, an investor in mainly small/micro capitalized quoted companies. Mark then established Intrinsic Capital LLP in 2007 as a regulated corporate and introductory business and extended the regulatory permission to include a retail investment management offering in 2015 seeking to add value with a straightforward, transparent and cost efficient service to high net worth and professional investors.

Mark Horrocks, his related parties and other members of his family have an interest in 4,422,947 Asimilar ordinary shares, representing 4.19% of Asimilar's issued share capital. On completion of the acquisition of ICJL, Mark Horrocks, his related parties and other members of his family will have an interest in 5,422,947 Asimilar ordinary shares, representing 5.10% of Asimilar's issued share capital.

Total Voting Rights

Application has been made for the Consideration Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 4 September 2020.

Following admission of the 1,000,000 Consideration Shares, the total issued share capital of the Company will be 106,361,443 Ordinary Shares, each with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

John Taylor, Chairman of Asimilar commented, "We are delighted to be able to announce our purchase of Intrinsic Capital (Jersey) Limited. The acquisition will provide a more benign taxation regime for our current portfolio and future investments.

In addition we are excited at the prospect of being able to acquire a significant holding in Dev Clever, a cutting edge technology company which we believe is well positioned to benefit from recent growth in the global ed-tech sector.

"We are also pleased at the potential of being able to welcome Mark Horrocks to the Board of Asimilar and believe his experience and professionalism in the area of small company investing will be a great asset to Asimilar in the future."

 

-Ends-

Contacts

Asimilar Group plc

 

John Taylor, Non-Executive Chairman

via Buchanan

 

 

Cairn Financial Advisers LLP

 

Sandy Jamieson / Liam Murray

Tel: +44 20 7213 0880

 

 

Peterhouse Capital Limited

 

Duncan Vasey / Lucy Williams

Tel: + 44 20 7220 9797

 

 

Buchanan Communications Limited

 

Richard Oldworth / Chris Lane

Tel: +44 (0) 20 7466 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQSSLSSFESSEFU
Date   Source Headline
30th Apr 20149:30 amRNSDirectorate Change
14th Apr 20147:00 amRNSBusiness Update
9th Apr 20149:00 amRNSReplacement announcement: Director resignation
9th Apr 20147:00 amRNSDirector Resignation
12th Mar 20147:00 amRNSNew Contract Wins valued at more than £0.5m
5th Mar 20147:00 amRNSNotice of AGM
21st Feb 20147:00 amRNSFinal Results
10th Feb 201411:00 amRNSTrading Update & Notice of Results
17th Dec 20137:00 amRNSChange of UK Head Office & Registered Office
28th Nov 201311:00 amRNSTrading Statement
16th Aug 20137:00 amRNSAppointment of Director and Grant of Share Options
26th Jun 20137:01 amRNSAppointment of Broker
26th Jun 20137:00 amRNSHalf Yearly Report
24th Jun 20137:00 amRNSNew contract wins
15th May 20138:41 amRNSResignation of NED & Appointment of Head of Ops
23rd Apr 201312:37 pmRNSResult of AGM
19th Apr 20137:00 amRNSChange of Adviser
18th Apr 20137:00 amRNSStmnt re Share Price Movement
28th Mar 20137:00 amRNSFinal Results for the Year Ended 30 September 2012
26th Mar 20139:47 amRNSPentagon Protection signs distribution agreement
18th Mar 20137:00 amRNSLoan Agreement
21st Feb 20137:00 amRNSNew Contract Win Valued at £1.9m
22nd Jan 20137:00 amRNSNew contract wins
8th Nov 20127:00 amRNSTrading Update and Result of General Meeting
8th Oct 20127:00 amRNSNew Contract Gains
18th Sep 20127:00 amRNSFurther Contract Gains
3rd Jul 20127:00 amRNSFurther Contract Gains
27th Jun 20127:00 amRNSIssue of Equity and Capitalisation of Loan
7th Jun 20129:17 amRNSInterim Results
30th Apr 20127:00 amRNSFurther Contract Gains
17th Apr 201212:24 pmRNSTotal Voting Rights
16th Apr 20124:33 pmRNSResult of AGM
16th Apr 20127:00 amRNSPENTAGON ANNOUNCES CONTRACT GAINS ACROSS THE GROUP
11th Apr 20124:10 pmRNSRestriction on New Share Authorities
3rd Apr 20123:10 pmRNSAdjournment of AGM
8th Mar 20129:30 amRNSNotice of AGM and Share Capital Reorganisation
7th Mar 201210:38 amRNSFinal Results
17th Nov 20117:00 amRNSTrading Update
8th Sep 20117:00 amRNSContract Gains
9th Aug 20117:00 amRNSContract Awards
28th Jul 20117:00 amRNSNew Contract Win
30th Jun 20119:01 amRNSHalf Yearly Report
24th May 201111:26 amRNSNew Contract Win
28th Apr 20114:52 pmRNSContract Award and Resignation of Director
15th Apr 20115:09 pmRNSResult of AGM
18th Mar 201110:00 amRNSDoc re. Report and Accounts / Related Pty Tran
18th Mar 20119:52 amRNSFinal Results
24th Nov 201012:36 pmRNSAppointment of Director
12th Nov 20104:30 pmRNSResult of GM
26th Oct 20107:00 amRNSAcquisition & Notice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.